Naropin and Rimactane

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

Rifampin or other rifamycins may decrease the plasma concentrations of ropivacaine. The mechanism is rifamycin induction of CYP450 1A2 and 3A4, the isoenzymes responsible for the metabolic clearance of ropivacaine. In 18 healthy volunteers, rifampin (600 mg once a day for 5 days) increased the mean area under the plasma concentration-time curve of a single 0.6 mg/kg IV dose of ropivacaine by 52% and 38% in nonsmokers and smokers, respectively, compared to placebo. In nonsmokers, rifampin increased the clearance of ropivacaine by 93% and shortened its half-life by 25%. In smokers, rifampin increased the clearance of ropivacaine by 47% and shortened its half-life by 20%. The reduced effect of rifampin seen in smokers may be due to induction of ropivacaine metabolism via CYP450 1A2 caused by smoking. In clinical practice, the interaction should have minimal impact on the quality and duration of local anesthesia produced by ropivacaine, since induction of CYP enzymes is not likely to affect local anesthetic before it enters the systemic blood circulation.

Naropin

Generic Name: ropivacaine

Brand name: Naropin, Naropin Polyamp, Naropin SDV, Naropin Novaplus

Synonyms: n.a.

What is Naropin?

Rimactane

Generic Name: rifampin

Brand name: Rifadin, Rifadin IV, Rimactane

Synonyms: n.a.

What is Rimactane?